Cancer Network Staff

Surgical updates for invasive breast cancer from the NCCN Breast Cancer meeting revealed insights on neoadjuvant endocrine therapy and SLNB omission.

Nivolumab improved 9-year recurrence-free survival compared with ipilimumab for resected stage III or IV melanoma in the phase 3 CheckMate 238 trial.

Irpagratinib demonstrated superior survival among patients with hepatocellular carcinoma who were pretreated with ICIs and mTKIs.

Supporting results for zenocutuzumab in patients with NRG1 fusion–positive CCA come from the phase 1/2 eNRGy trial.

Parul Barry, MD, discusses advances such as ultrahypofractionated radiation and the growing role of AI in streamlining workflows for breast cancer care.

J. Isabelle Choi, MD, outlined evidence-based strategies for radiation dose escalation in locoregionally advanced breast cancer.

Findings from a phase 2 study demonstrate the feasibility of conducting genomically driven trials among patients with meningiomas.

A phase 1/2 trial will evaluate N17350 in patients with pretreated, advanced solid tumors, such as head and neck neoplasms, NSCLC, and melanoma, among others.

Phase 1 QUILT-3.002 data showed that combining an IL-15 superagonist with rituximab achieved a 78% CR rate in those with rituximab-refractory disease.

Treatment with zanzalintinib plus atezolizumab led to improvements in OS and PFS vs regorafenib alone in patients with metastatic colorectal cancer.

Rivoceranib plus camrelizumab achieved a median OS of 23.8 months vs 15.2 months with sorafenib alone in patients with unresectable hepatocellular carcinoma.

Intensive surveillance and surgical resection for hepatic metastases from uveal melanoma improved long-term remission in a retrospective study.

Pembrolizumab administered before surgery in patients with desmoplastic melanoma led to high pathologic complete response rates in the SWOG S1512 trial.

In the phase 1/2 ReFocus trial, lirafugratinib demonstrated a median PFS of 11.3 months in the chemotherapy pretreated, FGR inhibitor-naïve CCA population.

Phase 2 PFLT-PC data revealed no significant disease was seen in 84% of patients treated with cooled laser focal therapy for prostate cancer at 3 months.

In the PATINA trial, adding palbociclib to maintenance therapy significantly improved progression-free survival in patients with HR+, HER2+ breast cancer.

The developer now plans to initiate a first-in-human clinical trial among patients with recurrent high-grade glioma.

Adding ANPEP and PIGR to a biomarker blood panel of CA19-9 and THBS2 significantly improved the detection rate of any-stage pancreatic cancer.

Following 2 prior CRLs from the FDA for the rivoceranib plus camrelizumab regimen in frontline HCC, the developer has again submitted an NDA to the FDA.

Data from the phase 3 PEAK trial demonstrate that bezuclastinib plus sunitinib may be favorable vs sunitinib alone in certain patients with GISTs.

Paxalisib combined with pembrolizumab and chemotherapy showed preliminary activity in patients with metastatic triple-negative breast cancer.

Patients with cervical cancer with cachexia, sarcopenia, and malnutrition had higher mortality when receiving concurrent chemoradiotherapy.

Zelenectide pevedotin demonstrated manageable safety among patients with advanced solid tumors in the phase 1/2 Duravelo-1 trial.

A total of 10.9% of patients experienced grade 5 AEs, yet no treatment-related deaths were reported with the nivolumab-based regimen in this HNSCC group.

The submission of an investigational new drug application for a uPAR-targeted imaging agent, FG001, supports a planned phase 2 trial in glioma.

In the ASCENT-04/KEYNOTE-D19 trial, sacituzumab govitecan plus pembrolizumab significantly extended PFS in patients with first-line metastatic TNBC.

Neoadjuvant radiation rarely produced RECIST responses, and a significant proportion of tumors increased in size in patients with retroperitoneal sarcoma.

Maveropepimut-S with pembrolizumab and low-dose cyclophosphamide yielded a 40% ORR and 90% DCR in platinum-sensitive high-grade endometrial cancer.

The FDA accepted the NDA for gedatolisib for HR+/HER2–, PIK3CA wild-type advanced breast cancer after it reduced the risk of disease progression or death.

Investigators used the NCCN Distress Thermometer to identify psychological distress in Nigerian patients with breast cancer in a cross-sectional study.